No Data
Express News | Monopar Therapeutics Files Prospectus Relates to Resale From Time to Time of up to 705,015 Shares of Common Stock by Selling Stockholder
JonesTrading Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $37
Monopar Therapeutics Price Target Raised to $37 From $9 at JonesResearch
Monopar Therapeutics Gains Buy Rating Following Strategic Agreement and Promising Phase III Results for Wilson's Disease Treatment
Monopar Therapeutics Analyst Ratings
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $22
No Data
No Data
